Readit NewsThe last line always gets me.
The new smartphone app.. Not so much. It looks more like some MBA types managed to solve "what is the cheapest thing we can get away with, lawfully?"As a result, the use case flow (IE the only way you can operate it..) of the app, goes as follows:
1 close the app 2 launch the app and sign in 3 do ONE action 4 enjoy the result of the action 5 repeat from 1..
You might wonder why that is.. Well, that is because your software is not allowed to display any errors - because that might indicate there were bugs.. So instead, whenever an error happens, you just display the '... still loading..' animation... forever. So, technically, there are no errors, no bugs.. "IT IS JUST TAKING TOO LONG TO RESPOND". (spoiler: it will NEVER respond, because hidden behind the screen, is a series of unhandled web api errors..)
But again, as an "internal" employee, I have seen our management claim all this is a huge success (client paid/pays).
Back to using it: When I have to interact with my doctor, I write the texts on my PC, and mail them to myself. Then I cut/paste them from gmail into this wonderful app.
https://www.newyorker.com/magazine/2018/11/12/why-doctors-ha...
In light of the fraudulent and scandalous approval of aducanumab [0] (which also targeted amyloid), such claims must be thoroughly referenced.
https://www.science.org/content/blog-post/aduhelm-again
https://www.science.org/content/blog-post/goodbye-aduhelm
https://www.science.org/content/blog-post/alzheimer-s-and-in...
It's not quite that simple, and the amyloid hypothesis doesn't claim it to be. It does, however, claim that it's the upstream cause of the disease, and if you stop it early enough, you stop the disease. But once you're already experiencing symptoms, there are other problem which clearing out the amyloid alone won't stop.
What’s more, lecanemab only improved scores by 0.45 points on an 18-point scale assessing patients’ abilities to think, remember, and perform daily tasks.
As I point out in another comment, the decline (from a baseline of ~3 points worse than a perfect score) during those 18 months is only 1.66 points in the placebo group, It's therefore very misleading to say this is an 18-point scale, so a 0.45 point benefit isn't clinically meaningful. A miracle drug with 100% efficacy would only achieve a 1.66 point slowdown.
Ok, maybe we’re just arguing different points here. I’ll grant that amyloids have something to do with all of this. I’m having a more difficult time understanding why one would suggest these drugs to a diagnosed Alzheimer’s patient at a point where it can no longer help.
Or is the long term thought that drugs like these will eventually be used a lot earlier as a prophylactic to those at high risk?
Yet despite decades of research, no treatment has been created that arrests Alzheimer’s cognitive deterioration, let alone reverses it.
Nowhere in the article does it mention that anti-amyloid therapies such as donanemab and lecanemab have so far successfully slowed decline by about 30%. They may not yet be "arresting" (fully stopping) the disease, but it's pretty misleading for the article to completely omit reference to this huge success.
We are currently in the midst of a misguided popular uprising against the amyloid hypothesis. There were several fraudulent studies on amyloid, and those responsible should be handled severely by the scientific community. But these fraudulent studies do not constitute the foundational evidence for the amyloid hypothesis, which remains very solid.
“Derek Lowe has worked on drug discovery for over three decades, including on candidate treatments for Alzheimer’s. He writes Science’s In The Pipeline blog covering the pharmaceutical industry.
“Amyloid is going to be — has to be — a part of the Alzheimer’s story, but it is not, cannot be a simple ‘Amyloid causes Alzheimer’s, stop the amyloid and stop the disease,'” he told Big Think.
“Although the effect of the drug will be described as being about a third, it consists, on average, of a difference of about 3 points on a 144-point combined scale of thinking and daily activities,” Professor Paresh Malhotra, Head of the Division of Neurology at Imperial College London, said of donanemab.
What’s more, lecanemab only improved scores by 0.45 points on an 18-point scale assessing patients’ abilities to think, remember, and perform daily tasks.
“That’s a minimal difference, and people are unlikely to perceive any real alteration in cognitive functioning,” Alberto Espay, a professor of neurology at the University of Cincinnati College of Medicine, told KFF Health News.
At the same time, these potentially invisible benefits come with the risk of visible side effects. Both drugs caused users’ brains to shrink slightly. Moreover, as many as a quarter of participants suffered inflammation and brain bleeds, some severe. Three people in the donanemab trial actually died due to treatment-related side effects.”
https://bigthink.com/health/alzheimers-treatments-lecanemab-...
And here’s a Lowe follow-up on hard data released later:
https://www.science.org/content/blog-post/lilly-s-alzheimer-...
5) Don't educate young people on what their degree would earn them.
So many young people think their hobby can become their career and pay for a nice life style. Unfortunately, it's not the case for many majors.
There were lots of reasons why you wouldn't want to buy one of these behemoths at the time (cost, weight, heat) but maybe the most significant was how bad NTSC video looked when you spread it across a 40" screen. I recently pulled out an old laserdisc player and connected it to a 65" OLED set and it looks absolutely terrible.